Abstract

Overexpression and frequent mutations in FMS-like tyrosine kinase-3 (FLT3) are considered risk factors for severe acute myeloid leukemia (AML). Hyperactive FLT3 induces premature activation of multiple intracellular signaling pathways, resulting in cell proliferation and anti-apoptosis. We conducted the computational modeling studies of 40 pyrimidine-4,6-diamine-based compounds by integrating docking, molecular dynamics, and three-dimensional structure–activity relationship (3D-QSAR). Molecular docking showed that K644, C694, F691, E692, N701, D829, and F830 are critical residues for the binding of ligands at the hydrophobic active site. Molecular dynamics (MD), together with Molecular Mechanics Poison–Boltzmann/Generalized Born Surface Area, i.e., MM-PB(GB)SA, and linear interaction energy (LIE) estimation, provided critical information on the stability and binding affinity of the selected docked compounds. The MD study suggested that the mutation in the gatekeeper residue F691 exhibited a lower binding affinity to the ligand. Although, the mutation in D835 in the activation loop did not exhibit any significant change in the binding energy to the most active compound. We developed the ligand-based comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) models. CoMFA (q2 = 0.802, r2 = 0.983, and = 0.698) and CoMSIA (q2 = 0.725, r2 = 0.965 and = 0.668) established the structure–activity relationship (SAR) and showed a reasonable external predictive power. The contour maps from the CoMFA and CoMSIA models could explain valuable information about the favorable and unfavorable positions for chemical group substitution, which can increase or decrease the inhibitory activity of the compounds. In addition, we designed 30 novel compounds, and their predicted pIC50 values were assessed with the CoMSIA model, followed by the assessment of their physicochemical properties, bioavailability, and free energy calculation. The overall outcome could provide valuable information for designing and synthesizing more potent FLT3 inhibitors.

Highlights

  • FMS-like tyrosine kinase-3 (FLT3) belongs to the type III tyrosine kinase receptor together with KIT, FMS, and platelet-derived growth factor receptor (PDGFR), which are involved in the differentiation, proliferation, and survival of hematopoietic progenitor cells [1]

  • As we conducted the Molecular dynamics (MD) simulation and 3D-QSAR study based on the docking pose, the verification of docking reliability is an important step

  • The development of FLT3 inhibitors is a promising strategy for achieving the therapeutic goal of the treatment of acute myeloid leukemia (AML)

Read more

Summary

Introduction

FLT3 belongs to the type III tyrosine kinase receptor together with KIT, FMS, and platelet-derived growth factor receptor (PDGFR), which are involved in the differentiation, proliferation, and survival of hematopoietic progenitor cells [1]. It is expressed by the stromal cells of bone marrow, placenta, and CD34+ cells, as well as the myeloid and B lymphoid cell lineage [2]. FL is the endogenous ligand of FLT3, which is expressed in bone marrow stromal cells, exists in a soluble form, or is bound to the membrane.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call